Studies and case series document increased skin laxity, facial volume loss, and accentuated wrinkles following weight reductions that occur within months of therapy initiation
Paracetamol remains an appropriate first-line option for mild to moderate pain, following NICE guidance
Protandim NRF2 shields against oxidative stress, supporting cellular repair and rejuvenation
Evidence and Effects Explained Ozempic (semaglutide) is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes and weight management
The study was a meta-analysis that included 21 trials (10 PIONEER and 11 SUSTAIN trials) involving 12,260 semaglutide users and 14,176 comparators
Surg., 187, 383-408, 1978